Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Chimeric antigen receptor (CAR) T-cell immunotherapy has gained significant attention in the past decade due to its considerable potential in the treatment of various types of malignancies, particularly hematological. While success has been achieved in a number of studies, and two CAR-T-cell products were recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (YESCARTA®, KYMRIAH®), this treatment modality continues to present challenges for clinical development. One major potential side effect is the ability of CAR-T products to induce host immune responses. Immunogenicity induction risk factors have been shown to be associated with the presence of non-human or partially human sequences in the CAR construct, suicide domain, or other components of the CAR-T, and also with the presence of residual viral proteins or other non-human origin proteins utilized as part of the gene editing step of CAR-T production. Both humoral (antibody-based) and cellular-type responses have been described, leading to various degrees of impact on CAR-T expansion and persistence, and therefore the overall safety and clinically meaningful response of the treatment. In this article we discuss various types of immune responses specific to CAR-T therapy, their impact on treatment outcome, and methodologies used to detect them.
Compliance with Ethical Standards
No funding was received in the preparation of this review.
Conflict of interest
Boris Gorovits is employed by the Pfizer Inc. which in the past has been involved in the development of CAR-T therapeutics. Eugen Koren is employed by the Precision for Medicine, which supports development of CAR-T therapeutics.
- 6.FDA. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma; 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm. Accessed 3 May 2019.
- 7.FDA. KYMRIAH (tisagenlecleucel); 2018. https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm573706.htm. Accessed 3 May 2019.
- 8.EMA. First two CAR-T cell medicines recommended for approval in the European Union; 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/06/news_detail_002983.jsp&mid=WC0b01ac058004d5c1. Accessed 3 May 2019.
- 14.Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther. 2010;17(10):1206–13.CrossRefGoogle Scholar
- 15.Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V, et al. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther. 2000;7(12):1067–75.CrossRefGoogle Scholar
- 24.Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.CrossRefGoogle Scholar
- 31.YESCARTA. Package Insert; 2017. https://www.fda.gov/media/108377/download. Accessed 3 May 2019.
- 32.KYMRIAH. Package Insert; 2017. https://www.fda.gov/media/107296/download. Accessed 3 May 2019.
- 34.Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl. 2010;16(9):1245–56.CrossRefGoogle Scholar
- 47.Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708–15.CrossRefGoogle Scholar
- 53.FDA. Immunogenicity testing of therapeutic protein products—developing and validating assays for anti-drug antibody detection. Guidance for industry; 2019. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm629728.pdf.
- 54.Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. CHMP; 2007.Google Scholar
- 67.Divgi CR, O’Donoghue JA, Welt S, O’Neel J, Finn R, Motzer RJ, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45(8):1412–21.Google Scholar